Literature DB >> 12430090

Cardiovascular disease in patients with chronic kidney disease.

Majd I Jaradat1, Bruce A Molitoris.   

Abstract

Cardiovascular disease (CVD) is the major cause of morbidity and mortality in patients with renal failure. Patients with chronic kidney disease have significant CVD, and carry a high cardiovascular burden by the time they commence renal replacement therapy (RRT). The severity of CVD that has been observed in dialysis patients lead to a growing body of research examining the pathogenesis and progression of CVD during the progression of chronic kidney disease (CKD) to end-stage renal disease (ESRD) (ie, predialysis phase). Multiple factors are involved in the development of CVD in CKD. More importantly, critical and key factors seem to develop early in the course of CKD, and result in preventable worsening of CVD in this patient population. Anemia is common in patients with CKD, and has been shown to have an independent role in the genesis of left ventricular hypertrophy (LVH) and subsequent CVD. Unfortunately, it is underdiagnosed and undertreated in patients with CKD. Early intervention, and better correction of anemia, seems to gain a great momentum in the prevention and management of CVD in CKD. Hypertension is another risk factor that has been targeted by the National Kidney Foundation Task Force on CVD in chronic kidney disease. This article reviews the different factors involved in the pathogenesis of CVD in CKD and the evidence supporting early and aggressive intervention. Copyright 2002, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12430090     DOI: 10.1053/snep.2002.35964

Source DB:  PubMed          Journal:  Semin Nephrol        ISSN: 0270-9295            Impact factor:   5.299


  7 in total

1.  Intravital imaging of the kidney in a rat model of salt-sensitive hypertension.

Authors:  Bradley T Endres; Ruben M Sandoval; George J Rhodes; Silvia B Campos-Bilderback; Malgorzata M Kamocka; Christopher McDermott-Roe; Alexander Staruschenko; Bruce A Molitoris; Aron M Geurts; Oleg Palygin
Journal:  Am J Physiol Renal Physiol       Date:  2017-04-12

2.  Treatment of elevated intracranial pressure with hyperosmolar therapy in patients with renal failure.

Authors:  Karen G Hirsch; Todd Spock; Matthew A Koenig; Romergryko G Geocadin
Journal:  Neurocrit Care       Date:  2012-12       Impact factor: 3.210

3.  Clinical characteristics of renal transplant recipients that underwent urologic surgery for de novo disease before and after transplantation.

Authors:  Kwan-Sik Bae; Jung-Sik Huh; Young-Joo Kim; Sung-Goo Chang
Journal:  J Korean Med Sci       Date:  2005-02       Impact factor: 2.153

4.  Adrenomedullin-RAMP2 system suppresses ER stress-induced tubule cell death and is involved in kidney protection.

Authors:  Ryuichi Uetake; Takayuki Sakurai; Akiko Kamiyoshi; Yuka Ichikawa-Shindo; Hisaka Kawate; Yasuhiro Iesato; Takahiro Yoshizawa; Teruhide Koyama; Lei Yang; Yuichi Toriyama; Akihiro Yamauchi; Kyoko Igarashi; Megumu Tanaka; Takashige Kuwabara; Kiyoshi Mori; Motoko Yanagita; Masashi Mukoyama; Takayuki Shindo
Journal:  PLoS One       Date:  2014-02-05       Impact factor: 3.240

5.  Safety and Efficacy of PDpoetin for Management of Anemia in Patients with end Stage Renal Disease on Maintenance Hemodialysis: Results from a Phase IV Clinical Trial.

Authors:  Abbas Norouzi Javidan; Heshmatollah Shahbazian; Amirhossein Emami; Mir Saeed Yekaninejad; Hassan Emami-Razavi; Masoumeh Farhadkhani; Ahmad Ahmadzadeh; Fazel Gorjipour
Journal:  Hematol Rep       Date:  2014-09-10

6.  Significance of Nitric Oxyde Saliva Concentration of the Patients with Renal Failure on Hemodialysis.

Authors:  Marina Vucijak-Grgurevic; Faris Zvizdic; Azra Durak-Nalbantic; Elmedina Jahic; Nerma Resic; Jasminko Huskic
Journal:  Mater Sociomed       Date:  2018-12

7.  Escalating antihypertensive medications in end-stage renal disease patients does not improve blood pressure control.

Authors:  Mihály Tapolyai; Jariatul Karim; Atif Fakhruddin
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-03       Impact factor: 3.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.